Join
Live feed
·
PRReleasevia Quantisnow
Gilead Sciences Inc. logo
Kymera Therapeutics Inc. logo

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

ByQuantisnow·Wall Street's wire, on your screen.
GILD· Gilead Sciences Inc.KYMR· Kymera Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GILD (Gilead Sciences Inc.), KYMR (Kymera Therapeutics Inc.) and more on Quantisnow.